Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

miRNAs in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments

Authors: Andreas Keller, Petra Leidinger, Anne Borries, Anke Wendschlag, Frank Wucherpfennig, Matthias Scheffler, Hanno Huwer, Hans-Peter Lenhof, Eckart Meese

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Deregulated miRNAs are found in cancer cells and recently in blood cells of cancer patients. Due to their inherent stability miRNAs may offer themselves for blood based tumor diagnosis. Here we addressed the question whether there is a sufficient number of miRNAs deregulated in blood cells of cancer patients to be able to distinguish between cancer patients and controls.

Methods

We synthesized 866 human miRNAs and miRNA star sequences as annotated in the Sanger miRBase onto a microarray designed by febit biomed gmbh. Using the fully automated Geniom Real Time Analyzer platform, we analyzed the miRNA expression in 17 blood cell samples of patients with non-small cell lung carcinomas (NSCLC) and in 19 blood samples of healthy controls.

Results

Using t-test, we detected 27 miRNAs significantly deregulated in blood cells of lung cancer patients as compared to the controls. Some of these miRNAs were validated using qRT-PCR. To estimate the value of each deregulated miRNA, we grouped all miRNAs according to their diagnostic information that was measured by Mutual Information. Using a subset of 24 miRNAs, a radial basis function Support Vector Machine allowed for discriminating between blood cellsamples of tumor patients and controls with an accuracy of 95.4% [94.9%-95.9%], a specificity of 98.1% [97.3%-98.8%], and a sensitivity of 92.5% [91.8%-92.5%].

Conclusion

Our findings support the idea that neoplasia may lead to a deregulation of miRNA expression in blood cells of cancer patients compared to blood cells of healthy individuals. Furthermore, we provide evidence that miRNA patterns can be used to detect human cancers from blood cells.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.CrossRefPubMed
2.
Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K: Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007, 132 (3 Suppl): 234S-242S. 10.1378/chest.07-1378.CrossRefPubMed
3.
Henschke CI, Yankelevitz DF: CT screening for lung cancer: update 2007. Oncologist. 2008, 13 (1): 65-78. 10.1634/theoncologist.2007-0153.CrossRefPubMed
4.
Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993, 75 (5): 843-854. 10.1016/0092-8674(93)90529-Y.CrossRefPubMed
5.
Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6 (11): 857-866. 10.1038/nrc1997.CrossRefPubMed
6.
Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6 (4): 259-269. 10.1038/nrc1840.CrossRefPubMed
7.
Sassen S, Miska EA, Caldas C: MicroRNA: implications for cancer. Virchows Arch. 2008, 452 (1): 1-10. 10.1007/s00428-007-0532-2.CrossRefPubMed
8.
Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007, 302 (1): 1-12. 10.1016/j.ydbio.2006.08.028.CrossRefPubMed
9.
Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, Cui Q: An analysis of human microRNA and disease associations. PLoS ONE. 2008, 3 (10): e3420-10.1371/journal.pone.0003420.CrossRefPubMedPubMedCentral
10.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18 (10): 997-1006. 10.1038/cr.2008.282.CrossRefPubMed
11.
Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, et al: Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008, 3 (9): e3148-10.1371/journal.pone.0003148.CrossRefPubMedPubMedCentral
12.
Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, D140-144. 10.1093/nar/gkj112. 34 Database
13.
Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008, D154-158. 36 Database
14.
Griffiths-Jones S, Moxon S, Marshall M, Khanna A, Eddy SR, Bateman A: Rfam: annotating non-coding RNAs in complete genomes. Nucleic Acids Res. 2005, D121-124. 33 Database
15.
Vorwerk S, Ganter K, Cheng Y, Hoheisel J, Stahler PF, Beier M: Microfluidic-based enzymatic on-chip labeling of miRNAs. N Biotechnol. 2008, 25 (2-3): 142-149. 10.1016/j.nbt.2008.08.005.CrossRefPubMed
16.
Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19 (2): 185-193. 10.1093/bioinformatics/19.2.185.CrossRefPubMed
17.
Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B. 1995, 57: 289-300.
18.
Hochberg Y: A sharper bonferroni procedure for multiple tests of significance. Biometrica. 1988, 75: 185-193. 10.1093/biomet/75.4.800.CrossRef
19.
Shannon C: A mathematical theory of communication. The Bell System Technical Journal. 1984, 27: 623-656.CrossRef
20.
Vapnik V: The Nature of Statistical Learning Theory. 2000, Springer, ISBN 978-0-387-98780-4, SecondCrossRef
21.
Team RDC: R: A Language and Environment for Statistical Computing. 2008, Vienna, Austria: R Foundation for Statistical Computing
22.
Keller A, Ludwig N, Comtesse N, Hildebrandt A, Meese E, Lenhof HP: A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors. BMC Bioinformatics. 2006, 7: 539-10.1186/1471-2105-7-539.CrossRefPubMedPubMedCentral
23.
Wilcoxon F: Individual comparisons by ranking methods. Biometric Bull. 1945, 1: 80-83. 10.2307/3001968.CrossRef
24.
Mann H, Wilcoxon F: On a test whether one of two random variables is stochastically larger than the other. Ann Mat Stat. 1947, 18: 50-60. 10.1214/aoms/1177730491.CrossRef
25.
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006, 9 (3): 189-198. 10.1016/j.ccr.2006.01.025.CrossRefPubMed
26.
Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ: MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA. 2008, 105 (5): 1516-1521. 10.1073/pnas.0707493105.CrossRefPubMedPubMedCentral
27.
Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, Marsh CB, Nana-Sinkam SP: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008, 373 (4): 607-612. 10.1016/j.bbrc.2008.06.090.CrossRefPubMed
28.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA family. Cell. 2005, 120 (5): 635-647. 10.1016/j.cell.2005.01.014.CrossRefPubMed
29.
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64 (11): 3753-3756. 10.1158/0008-5472.CAN-04-0637.CrossRefPubMed
30.
Tong AW: Small RNAs and non-small cell lung cancer. Curr Mol Med. 2006, 6 (3): 339-349. 10.2174/156652406776894554.CrossRefPubMed
31.
Stahlhut Espinosa CE, Slack FJ: The role of microRNAs in cancer. Yale J Biol Med. 2006, 79 (3-4): 131-140.PubMed
32.
Williams AE: Functional aspects of animal microRNAs. Cell Mol Life Sci. 2008, 65 (4): 545-562. 10.1007/s00018-007-7355-9.CrossRefPubMed
33.
Zhang B, Wang Q, Pan X: MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol. 2007, 210 (2): 279-289. 10.1002/jcp.20869.CrossRefPubMed
34.
Calin GA, Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006, 66 (15): 7390-7394. 10.1158/0008-5472.CAN-06-0800.CrossRefPubMed
35.
Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65 (21): 9628-9632. 10.1158/0008-5472.CAN-05-2352.CrossRefPubMed
36.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838. 10.1038/nature03702.CrossRefPubMed
37.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006, 103 (7): 2257-2261. 10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral
38.
Guo L, Huang ZX, Chen XW, Deng QK, Yan W, Zhou MJ, Ou CS, Ding ZH: Differential Expression Profiles of microRNAs in NIH3T3 Cells in Response to UVB Irradiation. Photochem Photobiol. 2009, 85 (3): 765-73. 10.1111/j.1751-1097.2008.00482.x.CrossRefPubMed
39.
Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, et al: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009, 125 (2): 345-52. 10.1002/ijc.24390.CrossRefPubMed
40.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, et al: A microRNA polycistron as a potential human oncogene. Nature. 2005, 435 (7043): 828-833. 10.1038/nature03552.CrossRefPubMedPubMedCentral
41.
Alvarez-Garcia I, Miska EA: MicroRNA functions in animal development and human disease. Development. 2005, 132 (21): 4653-4662. 10.1242/dev.02073.CrossRefPubMed
42.
Feitelson MA, Lee J: Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2007, 252 (2): 157-170. 10.1016/j.canlet.2006.11.010.CrossRefPubMed
Metadata
Title
miRNAs in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments
Authors
Andreas Keller
Petra Leidinger
Anne Borries
Anke Wendschlag
Frank Wucherpfennig
Matthias Scheffler
Hanno Huwer
Hans-Peter Lenhof
Eckart Meese
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-353

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

The striking geographical pattern of gastric cancer mortality in Spain: environmental hypotheses revisited

Research article

Certified causes of death in patients with mesothelioma in South East England

Research article

Comparison of breast cancer survival in two populations: Ardabil, Iran and British Columbia, Canada

Study protocol

A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiation alone regarding Event-Free Survival – CapRI-2

Research article

Ability of Group IVB metallocene polyethers containing dienestrol to arrest the growth of selected cancer cell lines

Research article

Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits